These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20332705)

  • 1. Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.
    Agretti P; De Marco G; Sansone D; Betterle C; Coco G; Dimida A; Ferrarini E; Pinchera A; Vitti P; Tonacchera M
    J Endocrinol Invest; 2010 Dec; 33(11):784-8. PubMed ID: 20332705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune aspects of vitiligo.
    Kemp EH; Waterman EA; Weetman AP
    Autoimmunity; 2001; 34(1):65-77. PubMed ID: 11681494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for an autoimmune pathogenesis of vitiligo.
    Ongenae K; Van Geel N; Naeyaert JM
    Pigment Cell Res; 2003 Apr; 16(2):90-100. PubMed ID: 12622785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitiligo autoantibodies are effective against melanoma.
    Fishman P; Azizi E; Shoenfeld Y; Sredni B; Yecheskel G; Ferrone S; Zigelman R; Chaitchik S; Floro S; Djaldetti M
    Cancer; 1993 Oct; 72(8):2365-9. PubMed ID: 8402450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.
    Kemp EH; Waterman EA; Hawes BE; O'Neill K; Gottumukkala RV; Gawkrodger DJ; Weetman AP; Watson PF
    J Clin Invest; 2002 Apr; 109(7):923-30. PubMed ID: 11927619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity.
    Norris DA; Kissinger RM; Naughton GM; Bystryn JC
    J Invest Dermatol; 1988 Jun; 90(6):783-9. PubMed ID: 3373009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmunity as an aetiological factor in vitiligo.
    Rezaei N; Gavalas NG; Weetman AP; Kemp EH
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients.
    Li Y; Yang M; Zhang R; Liu W; Zhang K; Wen W; Yi L; Wang Q; Hao M; Yang H; Chang J; Li J
    Immunol Res; 2016 Dec; 64(5-6):1150-1156. PubMed ID: 27417998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis of melanocytes in vitiligo results from antibody penetration.
    Ruiz-Argüelles A; Brito GJ; Reyes-Izquierdo P; Pérez-Romano B; Sánchez-Sosa S
    J Autoimmun; 2007 Dec; 29(4):281-6. PubMed ID: 17888626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo.
    Kemp EH; Gavalas NG; Gawkrodger DJ; Weetman AP
    Autoimmun Rev; 2007 Jan; 6(3):138-42. PubMed ID: 17289548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-thyroid peroxidase antibody and vitiligo: a controlled study.
    Daneshpazhooh M; Mostofizadeh G M; Behjati J; Akhyani M; Robati RM
    BMC Dermatol; 2006 Mar; 6():3. PubMed ID: 16526964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients.
    Gottumukkala RV; Gavalas NG; Akhtar S; Metcalfe RA; Gawkrodger DJ; Haycock JW; Watson PF; Weetman AP; Kemp EH
    Lab Invest; 2006 Aug; 86(8):781-9. PubMed ID: 16682974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes.
    Li DG; Hu WZ; Ma HJ; Liu W; Yang QQ; Zhao G
    Mol Med Rep; 2016 Aug; 14(2):1275-82. PubMed ID: 27277530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).
    Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP
    Clin Exp Immunol; 1997 Sep; 109(3):495-500. PubMed ID: 9328128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of thyroid dysfunction in patients with vitiligo.
    Hegedüs L; Heidenheim M; Gervil M; Hjalgrim H; Høier-Madsen M
    Acta Derm Venereol; 1994 Mar; 74(2):120-3. PubMed ID: 7911617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organ-specific autoantibodies in vitiligo patients and their relatives.
    Mandry RC; Ortíz LJ; Lugo-Somolinos A; Sánchez JL
    Int J Dermatol; 1996 Jan; 35(1):18-21. PubMed ID: 8838923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitiligo and polyglandular autoimmune disease with autoantibodies to melanin-producing cells. A new syndrome?
    Peserico A; Rigon F; Semenzato G; Caretto A; Pasini CV; Betterle C
    Arch Dermatol; 1981 Nov; 117(11):751-2. PubMed ID: 7316541
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibodies to melanocytes. Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis.
    Howanitz N; Nordlund JL; Lerner AB; Bystryn JC
    Arch Dermatol; 1981 Nov; 117(11):705-8. PubMed ID: 7316530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune vitiligo: detection of antibodies to melanin-producing cells.
    Hertz KC; Gazze LA; Kirkpatrick CH; Katz SI
    N Engl J Med; 1977 Sep; 297(12):634-7. PubMed ID: 331108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopathogenesis of vitiligo.
    Sandoval-Cruz M; García-Carrasco M; Sánchez-Porras R; Mendoza-Pinto C; Jiménez-Hernández M; Munguía-Realpozo P; Ruiz-Argüelles A
    Autoimmun Rev; 2011 Oct; 10(12):762-5. PubMed ID: 21334464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.